MAGEA4 and cancer: In cancer cells, MAGE-A4 proteins are processed into peptide fragments that are subsequently presented by human leukocyte antigens (HLAs) at the cell surface in a form that can be recognized by circulating T cells (7), leading to T-cell activation and cytolytic activity (4).